Deutsche Bank AG boosted its holdings in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 0.5% during the fourth quarter, Holdings Channel reports. The fund owned 136,920 shares of the biopharmaceutical company’s stock after purchasing an additional 696 shares during the quarter. Deutsche Bank AG’s holdings in SAGE Therapeutics were worth $13,113,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. FMR LLC grew its holdings in SAGE Therapeutics by 0.5% during the 4th quarter. FMR LLC now owns 7,033,076 shares of the biopharmaceutical company’s stock worth $673,698,000 after acquiring an additional 33,432 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the period. Vanguard Group Inc lifted its position in shares of SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the period. Bank of New York Mellon Corp lifted its position in shares of SAGE Therapeutics by 18.3% in the 4th quarter. Bank of New York Mellon Corp now owns 1,831,437 shares of the biopharmaceutical company’s stock worth $175,433,000 after purchasing an additional 283,077 shares during the period. Finally, BB Biotech AG lifted its position in shares of SAGE Therapeutics by 28.4% in the 4th quarter. BB Biotech AG now owns 1,375,229 shares of the biopharmaceutical company’s stock worth $131,733,000 after purchasing an additional 303,856 shares during the period.

Shares of NASDAQ SAGE opened at $167.66 on Tuesday. The company has a market capitalization of $8.03 billion, a PE ratio of -20.75 and a beta of 2.91. SAGE Therapeutics Inc has a 52-week low of $79.88 and a 52-week high of $177.14.

SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($3.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.89) by ($0.49). The company had revenue of $0.27 million for the quarter. During the same quarter in the prior year, the firm posted ($1.75) EPS. Equities research analysts forecast that SAGE Therapeutics Inc will post -12.47 earnings per share for the current fiscal year.

In related news, Director Steven M. Paul sold 49,461 shares of the business’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $161.02, for a total transaction of $7,964,210.22. Following the transaction, the director now owns 272,777 shares in the company, valued at approximately $43,922,552.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven M. Paul sold 1,543 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $161.62, for a total transaction of $249,379.66. Following the transaction, the director now owns 272,777 shares in the company, valued at approximately $44,086,218.74. The disclosure for this sale can be found here. Insiders have sold a total of 175,811 shares of company stock worth $27,771,729 in the last quarter. 5.10% of the stock is owned by corporate insiders.

A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 5th. ValuEngine downgraded shares of SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Canaccord Genuity set a $220.00 price target on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 8th. Morgan Stanley dropped their price target on shares of SAGE Therapeutics from $230.00 to $213.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 19th. Finally, Guggenheim assumed coverage on shares of SAGE Therapeutics in a research report on Friday, February 22nd. They issued a “buy” rating and a $205.00 price target on the stock. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $201.45.

COPYRIGHT VIOLATION WARNING: “Deutsche Bank AG Boosts Holdings in SAGE Therapeutics Inc (SAGE)” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/deutsche-bank-ag-boosts-holdings-in-sage-therapeutics-inc-sage/2965355.html.

SAGE Therapeutics Profile

SAGE Therapeutics, Inc operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders.

Further Reading: How to Invest in an Index Fund

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.